Efficacy of rebamipide for low-dose aspirin-related gastrointestinal symptoms.
about
Rebamipide does not protect against naproxen-induced gastric damage: a randomized double-blind controlled trial.Nonsteroidal anti-inflammatory drug-induced visible and invisible small intestinal injuryDetermination of the adequate dosage of rebamipide, a gastric mucoprotective drug, to prevent low-dose aspirin-induced gastrointestinal mucosal injury.Combined treatment with dipeptidyl peptidase 4 (DPP4) inhibitor sitagliptin and elemental diets reduced indomethacin-induced intestinal injury in rats via the increase of mucosal glucagon-like peptide-2 concentration.Effect of egualen sodium hydrate on small-intestinal mucosal damage induced by low-dose aspirin: a prospective randomized clinical trial.
P2860
Efficacy of rebamipide for low-dose aspirin-related gastrointestinal symptoms.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Efficacy of rebamipide for low-dose aspirin-related gastrointestinal symptoms.
@en
type
label
Efficacy of rebamipide for low-dose aspirin-related gastrointestinal symptoms.
@en
prefLabel
Efficacy of rebamipide for low-dose aspirin-related gastrointestinal symptoms.
@en
P2093
P2860
P356
P1476
Efficacy of rebamipide for low-dose aspirin-related gastrointestinal symptoms.
@en
P2093
Akari Hisamatsu
Kazuhiro Mizukami
Kazunari Murakami
Masaaki Kodama
Masahiro Uchida
Tadayoshi Okimoto
Toshio Fujioka
Yoshifumi Nakagawa
Yuka Hirashita
P2860
P304
P356
10.3164/JCBN.12-27
P577
2012-08-10T00:00:00Z